Entero Healthcare Solutions Limited’s Board of Directors has convened and approved the unaudited financial results for the quarter ended June 30, 2026. The results, both standalone and consolidated, were accompanied by limited review reports with an unmodified opinion from the statutory auditors. The board also reconstituted various committees, effective August 25, 2026.
Entero Healthcare Board Approves Financials
The Board of Directors at Entero Healthcare Solutions Limited met on August 7, 2026, to review and approve the company’s unaudited financial results for the first quarter of the fiscal year ending June 30, 2026. This includes both standalone and consolidated financial statements, which have been presented with limited review reports bearing an unmodified opinion from the company’s statutory auditors. The approval of these results aligns with regulatory requirements and provides stakeholders with timely financial information.
Committee Reconstitutions
In addition to the financial review, the Board also approved the reconstitution of several key committees. These changes are set to take effect from August 25, 2026. The reconstitution follows the completion of the tenure for Rajesh Shashikant Dalal as a Non-Executive Independent Director on August 24, 2026. The committees affected include the Audit Committee, Nomination and Remuneration Committee, and the Stakeholders Relationship Committee. Key individuals like Sandhya Gadkari Sharma and Sujesh Vasudevan will continue to play significant roles in these reconstituted committees, with Sandhya Gadkari Sharma appointed as Chairperson of the Audit Committee and Sujesh Vasudevan as Chairperson of the Stakeholders Relationship Committee. Prabhat Agrawal will continue as a Member of the Audit Committee, while Arun Sadhanandham will serve as a Member of the Nomination and Remuneration Committee and the Stakeholders Relationship Committee. Prem Sethi is appointed as a Member of the Stakeholders Relationship Committee.
Financial Highlights (Standalone)
For the quarter ended June 30, 2026, Entero Healthcare reported total income of ₹1,064.11 million, an increase from ₹789.32 million in the previous quarter. Total expenses stood at ₹1,018.06 million. Profit before exceptional items and tax was ₹46.05 million. After accounting for tax expenses of ₹11.48 million, the profit for the period stood at ₹34.57 million. Total comprehensive income for the quarter was ₹33.87 million. Earnings per share (basic and diluted) for the quarter were ₹0.79.
Financial Highlights (Consolidated)
On a consolidated basis for the quarter ended June 30, 2026, Entero Healthcare reported total income of ₹19,435.02 million. Total expenses amounted to ₹18,763.82 million. The profit before exceptional items and tax was ₹671.20 million. After tax expenses of ₹150.69 million, the profit for the period was ₹520.51 million. Total comprehensive income stood at ₹519.21 million. Earnings per share (basic and diluted) for the quarter were ₹8.77 and ₹8.76 respectively.
Trading Window Information
Further to a previous intimation dated June 23, 2026, the company also reminded that the trading window for dealing in the company’s securities would open 48 hours after the disclosure of the financial results. This information is available on the company’s website.
Source: BSE
